Merck’s once-monthly oral HIV prevention pill, MK-8527, advances to Phase III and may offer an accessible PrEP option in the future.

GEMORNA could turn out to be a sea change for biopharma firms pursuing mRNA-based medicines beyond traditional infectious disease vaccines.

The foundation is launching with an initial slate of grants to local scientific centers of excellence in Seattle.

Findings suggest that because the brain maps are preserved, it may, theoretically, be possible to restore movement to a ...

The open-source pipeline designs proteins with improved success rates for therapeutic targets, including gene editing proteins and allergens.

AbbVie has agreed to acquire Gilgamesh Pharmaceuticals’ lead pipeline asset bretisilocin, a clinical-stage candidate designed to treat moderate-to-severe major depressive disorder (MDD), for up to $1.

Blueprint for ovarian reserve cell development identifies critical development milestones, risk factors for hormone-related disorders.

Researchers have created a blueprint of how one of the world's most dangerous toxins, botulinum toxin, is structured, stabilized, delivered and released.

Antibodies from a person who had previously been infected with mpox provides full protection from severe illness and death in mice.

Single-cell proteomics with RNA sequencing uncover hidden gene expression dynamics in stem cell differentiation.

A scalable, standardized platform to produce consistent, high-quality extracellular vesicles (EVs) from induced mesenchymal stem cells (MSCs) was developed recently by researchers at Allife Medicine ...

Intuitive Machines and San Jacinto College are working on a training program for space-made biopharmaceuticals.